CancerNetwork® spoke with James R. Berenson, MD, founder, medical and scientific director, and president and chief executive officer of the Institute for Myeloma and Bone Cancer Research and private practitioner in West Hollywood, California, about whether data...
CancerNetwork® spoke with James R. Berenson, MD, president and medical director of the Berenson Cancer Center, and founder of the Institute for Myeloma & Bone Cancer Research, about toxicities associated with ruxolitinib (Jakafi) combination therapy, as well as...
Encouraging preclinical data foreground a clinical trial evaluating ruxolitinib (Jakafi) with selinexor (Xpovio) in patients with multiple myeloma, according to James R. Berenson, MD. CancerNetwork® spoke with James R. Berenson, MD, founder, medical and scientific...
CancerNetwork® spoke with James R. Berenson, MD, about the potential role that JAK inhibitors may play in the treatment of patients with multiple myeloma. The conversation focused on the rationale for researching this drug class as well as ongoing initiatives to...
The Exciting Launch of Myeloma BioBank: James R. Berenson, MD, Multiple Myeloma, specialist announced in an interview on Blood Cancers Today the exciting launch of a new company, Myeloma BioBank, which will offer blood and bone marrow samples for purchase. All...
Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients Reference: James R. Berenson, MD Berenson Cancer Center Article
Blood Journal: A Phase 1 Trial: Evaluating…Methylprednisolone: RE: ASH 2023 San Diego, CA December 9-11 Media Interviews Summary on: and others BLOOD is a very important medical journal. Article
James R. Berenson, MD: Can JAK Inhibition Help Overcome Lenalidomide Resistance in Myeloma? Early-phase experience with ruxolitinib suggests potential role in relapsed/refractory disease Video
Multiple Myeloma regimens significantly less effective in real-world treatment settings. In this study, researchers looked at a large group of patients in a registry who received a series of drug combinations for treatment of multiple myeloma. The analysis included...
Interviewed Dr. Berenson on his perspective on Abstract 1 & Abstract 2. Questions: Reaction to results — anything surprising? Most important take home message or clinical implication.
Has built many patient programs and over 8 integrated software platforms to help blood cancer patients learn more about their disease and better navigate their disease. Interviewed Dr. Berenson on phase 1 data and others. Outcomes of Triple Class Refractory Multiple...
(The Video Journal of Hematological Oncology) is an open-access video journal dedicated to providing trusted and up-to-date medical information to improve understanding of hematological cancers. Interviewed Dr. Berenson on phase 1 data and other ASH news. Dr...
In this webcast from the ‘New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Drs. James R. Berenson, Adam D. Cohen, Deepu Madduri, and Sham Mailankody discuss...
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Joseph Mikhael, MD, MEd, FRCPC, FACP, Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, Arizona, argued in favor of minimal residual disease (MRD) testing for patients...
First-Line Treatment Options & Side Effects – Video Advances in Treating Relapsed Multiple Myeloma – Video How Are Clinical Trials for Multiple Myeloma Structured? – Video here
On the heels of his study, Dr. James Berenson an oncologist specializing in multiple myeloma —announced his latest findings and with his cancer patients, shared their challenging experiences during this pandemic. Article
Multiple myeloma (MM) patients are at higher risk for severe COVID-19. Their mRNA vaccination response against SARS-CoV-2 is unknown. Thus, we analyzed responses to mRNA vaccination against COVID-19 among these patients... Go to article Click Here
New name, logo, and business unit alignment introduced as part of an extensive rebranding initiative LOS ANGELES, Nov. 11, 2020 /PRNewswire/ -- Berenson Cancer Center, a world class multiple myeloma cancer research, diagnostic and treatment center has completed an...
Survival and treatments are improving for this type of blood cancer You don't expect to break a rib while doing light housekeeping. Similarly, you wouldn't think your worsening back pain might be caused by a type of blood cancer. However, these are among classic...
Abstract Tumor necrosis factor receptor-associated factor 6 (TRAF6) has been implicated in polyubiquitin-mediated IL-1R/TLR signaling through activation of IκB kinase (IKK) to regulate the NF-κB and JNK signaling pathways. Here, TRAF6 protein was determined to be...
Michael Ghermezi, Mingjie Li, Suzie Vardanyan, Nika Manik Harutyunyan, Jillian Gottlieb, Ariana Berenson, Tanya M. Spektor, Claudia Andreu-Vieyra, Sophia Petraki, Eric Sanchez, Kyle Udd, Cathy S. Wang, Regina A. Swift, Haiming Chen, James R Berenson Haematologica...
There appears to be marked improvement in overall survival in people with multiple myeloma, according to a study involving 264 individuals. Participants all had multiple myeloma with an initial visit occurring between 2004 and 2014. They had treatment at a clinic that...
Ariana Berenson Suzie Vardanyan Michael David James Wang Nika Manik Harutyunyan Jillian Gottlieb Ran Halleluyan Tanya M. Spektor Kyle A. Udd Shahrooz Eshaghian Youram Nassir Benjamin Eades Regina Swift James R. Berenson Abstract New classes of drugs including the...
Eric Sanchez, Abigail Gillespie, George Tang, Morgan Ferros, Nika Manik Harutyunyan, Suzie Vardanyan, Jillian Gottlieb, Mingjie Li, Cathy S. Wang, Haiming Chen and James R. Berenson DOI: 10.1158/1078-0432.CCR-15-2224 Published July 2016 Abstract Purpose: Reduced...
Abstract Multiple myeloma (MM) is characterized by the enhanced production of the same monoclonal immunoglobulin (M-Ig or M protein). Techniques such as serum protein electrophoresis and nephelometry are routinely used to quantify levels of this protein in the serum...
Abstract Elotuzumab, an immunostimulatory SLAMF7-targeting monoclonal antibody, induces myeloma cell death with minimal effects on normal tissue. In a previous phase 3 study in patients with relapsed/refractory multiple myeloma (RRMM), elotuzumab (10 mg/kg, ∼3-hour...
James R. Berenson, Alan Cartmell, Alberto Bessudo, Roger M. Lyons, Wael Harb, Dimitrios Tzachanis, Richy Agajanian, Ralph Boccia, Morton Coleman, Robert A. Moss, Robert M. Rifkin, Priti Patel, Sandra Dixon, Ying Ou, Janet Anderl, Sanjay Aggarwal and Jesus G. Berdeja...
J R Berenson1,2,3, J D Hilger2, O Yellin2, R Dichmann4, D Patel-Donnelly5, R V Boccia6, A Bessudo7, L Stampleman8, D Gravenor9, S Eshaghian10, Y Nassir11, R A Swift3 and R A Vescio10 Department of Hematology/Oncology, Institute for Myeloma and Bone Cancer Research,...
James R Berenson, MD, Tanya M Spektor, PhD, and James Wang Institute for Myeloma & Bone Cancer Research; James R Berenson, MD, Inc; and ONCOtherapeutics, West Hollywood, California Correspondence: James R Berenson, MD; jberenson@imbcr.org. Disclosures: Dr Berenson is...
Clinical Advances in Hematology & Oncology Authors: James R. Berenson, MD, Claudia Andreu-Vieyra, PhD, Sergio Giralt, MD...
Interview with Debra Berenson, myeloma patient advocate, wife of myeloma expert Dr. James Berenson, and author of the book, I HAVE WHAT? Debra has collected stories, insights, and tools for and from patients and their families with myeloma and related diseases. The...
What: Myeloma is a disease in your bone marrow. Inside your bone marrow are the cells that make your blood, your red cells, your white cells, and your platelets. This plays a key role in maintaining the strength of the bone. Why: There have been several recent...
By Clinical Advances in Hematology & Oncology March 2015, Volume 13, Issue 3 Multiple myeloma is an incurable disease, and patients who respond to treatment eventually relapse—which makes long-term maintenance therapy an appealing option. But is a treatment with...
Do you feel the Love? The New Year is here. Perhaps you have been newly diagnosed? Whether a Myeloma warrior, or new to the world of MM, talking about the disease with loved ones can be difficult, at best. What is Multiple Myeloma anyway? It’s hard enough to...
Tommy, who has been Dr. Berenson’s able assistant for many years, has a passion for athletics and training. In July 2013, he started Team IMBCR at a time when he was also participating in several marathons, half-marathons and trail running and half iron distance...
Abstract No: 8594 Background: Carfilzomib (CFZ) is a selective proteasome inhibitor approved in the US for the treatment of relapsed and refractory multiple myeloma (MM). This multicenter, single-arm phase 1/2 study (NCT01677858) is evaluating the safety and efficacy...
Myeloma news from the 2014 annual meeting of the American Society of Clinical Oncology has included updates on proteasome inhibitors, overcoming drug resistance, monoclonal antibodies and more. In this brief video, Dr. James Berenson, a leading myeloma researcher and...
Original Article Writen by: Robert Carlson - Oncology Times NEW YORK—Treatment regimens for relapsed/refractory multiple myeloma have become plentiful in the past few years, with a panoply of options. Consequently, “the old rules no longer apply,” says James Berenson,...
More Is Not Better Claudia Andreu-Vieyra, Ph.D and James Berenson, M.D. Multiple myeloma (MM) is the most common primary malignancy of the bone marrow.1, The 5-year survival rate for MM patients has increased from 25% in 1975 to almost 40% due to newer and more...
ORIGINAL STORY: Click Here. INSIDE EDITION: Airdate: 02/12/2014 There is an outpouring of support for legendary broadcaster Tom Brokaw as he bravely battles bone marrow cancer. Brokaw stepped down as anchor of the NBC Nightly News in 2004. He was diagnosed last August...
In response to NBC News Special Correspondent Tom Brokaw’s announcement that he has been diagnosed with multiple myeloma, a rare blood cancer of malignant cells found in the bone marrow, leading physician Dr. James Berenson is encouraged that Mr. Brokaw is receiving...
Dr. James Berenson, from the Institute for Myeloma & Bone Cancer Research, discusses the importance of weighing risks and benefits when choosing a myeloma treatment path. Dr. Berenson also discusses why he feels that having a variety of current treatment options,...
First, we have uncovered a new serum marker for multiple myeloma which is a protein called B-cell maturation antigen or BCMA for short. This protein is shed off the myeloma cells into the blood. We have shown that the levels of BCMA predict outcomes for myeloma...
Dr. James Berenson discusses the importance of using maintenance therapies with limited short- or long-term side effects, in particular avoiding therapies that have long-term toxicity. Dr. Berenson expresses his excitement that within the next few years there is hope...
New drugs provide powerful options, but little consensus on standard treatments New York—There is a profound disagreement over whether early stem cell transplant (SCT) should still be characterized as a standard early intervention for multiple myeloma (MM), even in...
Posted By Navneet Ramesh and Maike Haehle on the Myeloma Beacon on Aug 31, 2013 2:01 Researchers recently reported updated survival rates for multiple myeloma patients in the United States. The results show that survival has improved steadily – and markedly –...
The Institute for Myeloma & Bone Cancer Research (IMBCR) is proud to announce that it is an official charity of the 2014 ASICS LA Marathon that will take place on Sunday, March 9th, 2014. We hope that you will become involved in this event, and, as a member of...
There have been several recent breakthroughs for the treatment of multiple myeloma patients that have led to new therapeutic options. With regards to newer agents, there are a number of new drugs in development. The most promising are the antibody-based treatments...
Br J Haematol. 2013 Feb;160(3):321-30. doi: 10.1111/bjh.12129. Epub 2012 Nov 15. Berenson JR, Yellin O, Bessudo A, Boccia RV, Noga SJ, Gravenor DS, Patel-Donnelly D, Siegel RS, Kewalramani T, Gorak EJ, Nassir Y, Swift RA, Mayo D. Abstract Bendamustine, active in...
Leuk Res. 2012 Nov;36(11):1422-7. doi: 10.1016/j.leukres.2012.07.018. Epub 2012 Aug 17. Sanchez E, Li M, Li J, Wang C, Chen H, Jones-Bolin S, Hunter K, Ruggeri B, Berenson JR. Abstract Preclinical and clinical studies have shown that proteasome inhibitors (PIs) have...
Dr. Berenson will be the featured Myeloma Cure Talk Panel member on this November 29th, 2012 @ 6:00 PM EST broadcast. You can sign up for the broadcast here. The discussion will cover Dr. Berenson's multiple myeloma treatment philosophy and preferred treatment...
Updates in the Treatment of Multiple Myeloma (PDF)
Br J Haematol. 2012 Sep;158(6):727-38. doi: 10.1111/j.1365-2141.2012.09241.x. Epub 2012 Jul 18. Sanchez E, Li M, Kitto A, Li J, Wang CS, Kirk DT, Yellin O, Nichols CM, Dreyer MP, Ahles CP, Robinson A, Madden E, Waterman GN, Swift RA, Bonavida B, Boccia R, Vescio RA,...
The Institute for Myeloma & Bone Cancer Research (IMBCR) is pleased to announce the dedication of a newly designed artwork for IMBCR. Artist, Ted Kirby, named the artwork “Determination”, in honor of all those who are determined to cure Multiple Myeloma. Please...
Dr. James Berenson helps patients understand new FDA recommendations regarding the use of lenalidomide (Revlimid) and a study from Sweden regarding increased risk of blot clots for myeloma patients. Dr. Berenson also previews the topics that he believes will be...
Oncotherapeutics, an oncology specific Contract Research Organization (CRO) specializing in the oversight and management of clinical trails for cnacer, will present final results from a multicenter clinical trial at the American Society of Hematology Annual Meeting in...
Leuk Res. 2011 Mar;35(3):373-9. doi: 10.1016/j.leukres.2010.06.026. Epub 2010 Jul 21. Sanchez E, Shen J, Steinberg J, Li M, Wang C, Bonavida B, Chen H, Li ZW, Berenson JR. Abstract Panobinostat (LBH589) is a potent histone deacetylase inhibitor (HDACi) that has shown...
The results of this landmark study should be welcomed news to cancer patients across the world suffering from the debilitating effects of painful vertebral compression fractures,” said Dr. James Berenson, the study's first author and Medical and Scientific Director of...
